Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 1
Submit an article Journal homepage
746
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

Rong DengGenentech Inc, South San Francisco, CA, USA; Correspondence[email protected]
View further author information
,
Leonid GibianskyQuantPharm, LLC, North Potomac, MD, USA; View further author information
,
Tong LuGenentech Inc, South San Francisco, CA, USA; View further author information
,
Xiaobin LiGenentech Inc, South San Francisco, CA, USA; View further author information
,
Dan LuGenentech Inc, South San Francisco, CA, USA; View further author information
,
Chunze LiGenentech Inc, South San Francisco, CA, USA; View further author information
,
Sandhya GirishGenentech Inc, South San Francisco, CA, USA; View further author information
,
Jue WangGenentech Inc, South San Francisco, CA, USA; View further author information
,
Michelle BoyerF. Hoffmann – La Roche Ltd, Welwyn Garden City, UK; View further author information
,
Noopur ShankarGenentech Inc, South San Francisco, CA, USA; View further author information
,
Kathryn HumphreyF. Hoffmann – La Roche Ltd, Welwyn Garden City, UK; View further author information
,
Kevin J. FreiseAbbVie, North Chicago, IL, USA; View further author information
,
Ahmed Hamed SalemAbbVie, North Chicago, IL, USA; ;Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; ORCID Iconhttp://orcid.org/0000-0002-9261-1583View further author information
ORCID Icon,
John F. SeymourRoyal Melbourne Hospital, Peter MacCallum Cancer Centre, & University of Melbourne, Melbourne, Australia; View further author information
,
Arnon P. KaterDepartment of Hematology, Cancer Center Amsterdam, Hovon CLL Study Group, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsView further author information
&
Dale MilesGenentech Inc, South San Francisco, CA, USA; View further author information
 show all
Pages 56-65 | Received 08 Mar 2019, Accepted 06 Aug 2019, Published online: 24 Sep 2019

References

  • Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
  • National Cancer Institute. 2018. 6 May. NCI Dictionary of Cancer Terms. NCI. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cll-sll. Accessed 2019 2 July.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
  • Highlights of prescribing information. VENCLEXTA™ (venetoclax) tablets, for oral use. Initial US Approval: 2016. Revised: May 2019. North Chicago, IL: Abbvie Inc.
  • Freise KJ, Jones AK, Eckert D, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet. 2017;56:515–523.
  • Parikh A, Gopalakrishnan S, Freise KJ, et al. Exposure–response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2018;59:871–879.
  • Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230–240.
  • Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–1120.
  • Jones AK, Freise KJ, Agarwal SK, et al. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18:1192–1202.
  • Agarwal SK, Hu B, Chien D, et al. Evaluation of rifampin's transporter inhibitory and CYP3a inductive effects on the pharmacokinetics of venetoclax, a BLC-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. 2016;56:1335–1343.
  • Salem AH, Agarwal SK, Dunbar M, et al. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56:1355–1361.
  • Freise KJ, Shebley M, Salem AH. Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model. J Clin Pharmacol. 2017;57:796–804.
  • Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83:846–854.
  • Freise KJ, Jones AK, Menon RM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. 2017;35:679–684.
  • Deng R, Gibiansky L, et al. Bayesian population model of the pharmacokinetics of venetoclax in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from the Phase 3 MURANO study. Clin Pharmacokinet. 2019. DOI:10.1007/s40262-019-00788-8
  • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
  • Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778.
  • Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
  • Ma S, Brander DM, Seymour JF, et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood. 2015;126:830.
  • Jones J, Mato AR, Coutre S, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. Blood. 2015;126:715.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.